Observational studyWorld journal of surgical oncology2025
Risk factors and prognosis of postoperative early relapse after neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a retrospective study.
Observational study in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to identify risk factors associated with early postoperative relapse and evaluate their impact on survival outcomes after neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (LA-ESCC), thereby informing strategies to optimize postoperative clinical management.
methodsPatients with LA-ESCC who underwent neoadjuvant therapy followed by surgical resection at West China Hospital between January 2018 and December 2023 were screened and enrolled. Patients were categorized into early relapse (≤ 6 months) and late relapse (> 6 months) groups based on the interval from surgery to relapse.
resultsA total of 183 LA-ESCC patients who received neoadjuvant therapy followed by surgical resection were included, with 79 experiencing early relapse and 104 experiencing late relapse. Logistic regression analysis showed that postoperative TNM stage III-IV, ypN + stage, R1 resection, lymphovascular invasion (LVI), perineural invasion (PI), and absence of postoperative adjuvant therapy were risk factors for early relapse (p < 0.05). Multivariate regression further identified R1 resection as an independent predictor (p < 0.05). Cox regression analysis demonstrated that LI was a prognostic factor for overall survival (OS) in patients with early relapse (p = 0.045). Kaplan-Meier analysis revealed significantly reduced OS (12.5 months vs. 26.9 months, HR = 2.96, p < 0.001) and survival after relapse (SAR) (5.9 months vs. 11.0 months, HR = 1.81, p < 0.001) in the early relapse group compared to the late relapse group. However, relapse patterns did not differ significantly between groups (p > 0.05).
conclusionR1 resection is an independent risk factor for rapid postoperative relapse in LA-ESCC patients following neoadjuvant therapy. Furthermore, LVI significantly affects patients survival outcomes, and early relapse was strongly associated with reduced overall survival (OS).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.